Lawsuits have been filed against Janssen Pharmaceuticals alleging that Invega can increase a user’s risk of developing gynecomastia and/or hyperprolactinemia. These lawsuits accuse the company of releasing a defective drug into the marketplace and failing to provide adequate warnings for the dangerous side effects associated with Invega. Allegedly, Janssen knew that the drug could cause male users to produce higher-than-normal levels of prolactin (a hormone that stimulates milk production in women after childbirth), yet failed to warn patients about this risk.
Drug companies are required to fully and accurately disclose any and all side effects associated with their products, and may be held liable in court when they fail to do so.
The lawsuits against Janssen allege that Invega is defective, and that the manufacturer misled doctors and patients about the safety and efficacy of the drug, and marketed it for off-label, unapproved uses. These suits have been filed on behalf of patients who, after using Invega, allegedly developed serious side effects including hyperprolactinemia, gynecomastia, rapid weight gain, diabetes mellitus, pancreatitis, metabolic syndrome, tardive dyskinesia (involuntary movements, usually of the face), and other adverse effects.
Specifically, the suits allege that:
It is believed that Invega promotes pituitary gland secretion, which releases different hormones including prolactin, a hormone only found naturally in breastfeeding women. In turn, those who use these antipsychotic drugs may be at risk for developing hyperprolactinemia or abnormal breast tissue.
The active ingredient in Invega, paliperidone, is believed to be responsible for elevating prolactin levels in a way similar to that of Janssen’s other antipsychotic, Risperdal (risperidone). According to the current prescribing information for Invega, Risperdal users have reported significantly higher levels of prolactin in their blood, when compared to users of different antipsychotics. Risperdal users have also reported being diagnosed with gynecomastia and have sued Janssen for compensation.
In 2012, the FDA performed a post-market adverse event review on Invega after the drug was approved for use in adolescents. According to the agency’s review, a 16-year-old boy developed breasts just three months after using Invega. Although follow-up information on treatment was unavailable in this case, many who develop gynecomastia only have one option for treatment: mastectomy.
Before commenting, please review our comment policy.
ClassAction.org is a group of online professionals (designers, programmers and writers) with years of experience in the legal industry. We work closely with class action and mass tort attorneys across the country and help with investigations into corporate wrongdoing.